Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neurocrine ( (NBIX) ) has issued an announcement.
Neurocrine Biosciences announced the appointment of Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts, who will remain as a strategic advisor. Dr. Keswani brings over 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs, enhancing the company’s capabilities as it explores new therapeutic modalities.
More about Neurocrine
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to discovering and developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company offers FDA-approved treatments for conditions such as tardive dyskinesia and Huntington’s disease chorea, and has a diverse pipeline of compounds in mid- to late-phase clinical development.
YTD Price Performance: -25.37%
Average Trading Volume: 1,334,899
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.26B
See more data about NBIX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts